Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms RED-HF; RED-HF Trial
- Sponsors Amgen
- 05 Oct 2021 Planned number of patients changed from 2600 to 3400.
- 01 Oct 2015 Pooled analysis of 2 studies of total 4854 patients including patients from this TREAT trial and other RED-HF trial [see CTP 700155505] were published in the European Journal of Heart Failure.
- 17 May 2014 New trial record